RU2184734C2 - S-омепразол в нейтральной форме, способы его получения, фармацевтическая композиция, содержащая s-омепразол в нейтральной форме, и способ лечения связанного с желудочной кислотой состояния - Google Patents

S-омепразол в нейтральной форме, способы его получения, фармацевтическая композиция, содержащая s-омепразол в нейтральной форме, и способ лечения связанного с желудочной кислотой состояния Download PDF

Info

Publication number
RU2184734C2
RU2184734C2 RU99116303/04A RU99116303A RU2184734C2 RU 2184734 C2 RU2184734 C2 RU 2184734C2 RU 99116303/04 A RU99116303/04 A RU 99116303/04A RU 99116303 A RU99116303 A RU 99116303A RU 2184734 C2 RU2184734 C2 RU 2184734C2
Authority
RU
Russia
Prior art keywords
omeprazole
neutral
solution
organic solvent
omeprasol
Prior art date
Application number
RU99116303/04A
Other languages
English (en)
Russian (ru)
Other versions
RU99116303A (ru
Inventor
Мартин БОХЛИН
Кароль ХОРВАТ
УНГЕ Сверкер Вон
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20405146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2184734(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU99116303A publication Critical patent/RU99116303A/ru
Application granted granted Critical
Publication of RU2184734C2 publication Critical patent/RU2184734C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU99116303/04A 1996-12-20 1997-12-16 S-омепразол в нейтральной форме, способы его получения, фармацевтическая композиция, содержащая s-омепразол в нейтральной форме, и способ лечения связанного с желудочной кислотой состояния RU2184734C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9604793A SE510666C2 (sv) 1996-12-20 1996-12-20 Nya Kristallmodifikationer
SE9604793-1 1996-12-20

Publications (2)

Publication Number Publication Date
RU99116303A RU99116303A (ru) 2001-05-27
RU2184734C2 true RU2184734C2 (ru) 2002-07-10

Family

ID=20405146

Family Applications (1)

Application Number Title Priority Date Filing Date
RU99116303/04A RU2184734C2 (ru) 1996-12-20 1997-12-16 S-омепразол в нейтральной форме, способы его получения, фармацевтическая композиция, содержащая s-омепразол в нейтральной форме, и способ лечения связанного с желудочной кислотой состояния

Country Status (36)

Country Link
US (1) US6162816A (https=)
EP (1) EP0946547B1 (https=)
JP (1) JP4402174B2 (https=)
KR (1) KR20000069595A (https=)
CN (1) CN1109684C (https=)
AR (1) AR010361A1 (https=)
AT (1) ATE236898T1 (https=)
AU (1) AU730129B2 (https=)
BR (1) BR9714059A (https=)
CA (1) CA2274076C (https=)
CZ (1) CZ294784B6 (https=)
DE (1) DE69720774T2 (https=)
DK (1) DK0946547T3 (https=)
EE (1) EE03923B1 (https=)
EG (1) EG24414A (https=)
ES (1) ES2194231T3 (https=)
HU (1) HU227589B1 (https=)
ID (1) ID21850A (https=)
IL (1) IL130450A0 (https=)
IS (1) IS1981B (https=)
MY (1) MY117032A (https=)
NO (1) NO317191B1 (https=)
NZ (1) NZ336024A (https=)
PL (1) PL190377B1 (https=)
PT (1) PT946547E (https=)
RS (1) RS49685B (https=)
RU (1) RU2184734C2 (https=)
SA (1) SA97180739B1 (https=)
SE (1) SE510666C2 (https=)
SI (1) SI0946547T1 (https=)
SK (1) SK285151B6 (https=)
TR (1) TR199901410T2 (https=)
TW (1) TW538039B (https=)
UA (1) UA55436C2 (https=)
WO (1) WO1998028294A1 (https=)
ZA (1) ZA9711046B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014035295A1 (ru) 2012-08-30 2014-03-06 Dikovskiy Alexander Vladimirovich Фармацевтическая композиция для лечения гастроэзофагеальной рефлюксной болезни

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SI20019A (sl) 1998-07-13 2000-02-29 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
IL142703A (en) 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
JP3926936B2 (ja) * 1998-11-16 2007-06-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホキシド誘導体・アセトン錯体およびその製造法
SE9804003D0 (sv) * 1998-11-23 1998-11-23 Astra Ab A method of producing drug particles
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound
JP2000344739A (ja) * 1999-06-01 2000-12-12 Sumitomo Chem Co Ltd Ｎ−保護−アゼチジン−２−カルボン酸の製造方法
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
CN100562318C (zh) * 2000-05-15 2009-11-25 武田药品工业株式会社 晶体的制备方法
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
JP5412023B2 (ja) 2000-08-04 2014-02-12 武田薬品工業株式会社 ベンズイミダゾール化合物の塩およびその用途
SI20875A (sl) * 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EP2260837A1 (en) 2001-06-01 2010-12-15 Pozen, Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
GB2376231A (en) 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
DE60311809T2 (de) * 2002-06-27 2007-11-22 Dr. Reddy's Laboratories Ltd. Verfahren zur herstellung optisch reiner oder optisch angereicherter sulfoxidverbindungen einschliesslich amorphen esomeprazols und dessen salze
US7169793B2 (en) 2002-06-27 2007-01-30 Dr. Reddy's Laboratories Limited Process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
EP1546131A1 (en) * 2002-08-30 2005-06-29 Dr. Reddy's Laboratories Ltd. Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof
EP2596791B1 (en) 2002-10-16 2015-04-01 Takeda Pharmaceutical Company Limited Stable solid preparations
BR0315574A (pt) * 2002-10-22 2005-09-20 Ranbaxy Lab Ltd Forma amorfa de esomeprazol, composição farmacêutica contendo o mesmo e processo para sua preparação
WO2004046134A2 (en) * 2002-11-18 2004-06-03 Dr. Reddy's Laboratories Limited Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation
BRPI0407906A (pt) * 2003-02-28 2006-02-14 Ranbaxy Lab Ltd polimorfos de s-omeprazol
DE602004032524D1 (de) 2003-03-24 2011-06-16 Eisai R&D Man Co Ltd Verfahren zur herstellung von amorphem rabeprazole-natrium-salz
EP1633736A1 (en) * 2003-05-05 2006-03-15 Ranbaxy Laboratories Limited Barium salt of benzimidazole derivative
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
SE0400410D0 (sv) 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
CN103121992A (zh) * 2004-06-24 2013-05-29 阿斯利康(瑞典)有限公司 制备用于制备艾美拉唑钠盐的结晶修饰物的新方法
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20090298884A1 (en) * 2005-05-06 2009-12-03 Glenmark Generics Ltd. Esomeprazole Strontium Salt, Process For Its Preparation and Pharmaceutical Compositions Containing Same
WO2006131338A2 (en) * 2005-06-08 2006-12-14 Lek Pharmaceuticals D.D. Crystalline solvate of omeprazole sodium
EP1891043A1 (en) * 2005-06-15 2008-02-27 Hetero Drugs Limited Amorphous esomeprazole hydrate
NL2000126C2 (nl) * 2005-07-15 2008-01-29 Solvay Werkwijze voor de vervaardiging van eptifibatide.
US20070043085A1 (en) * 2005-08-19 2007-02-22 Glenmark Pharmaceuticals Limited Process for the preparation of amorphous form of neutral esomeprazole
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
EP1948637A4 (en) * 2005-11-14 2010-09-08 Hetero Drugs Ltd PROCESS FOR AMORPHES ESOMEPRAZOLE
WO2007067128A1 (en) * 2005-12-05 2007-06-14 Astrazeneca Ab New process for the preparation of esomeprazole non-salt form
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
ATE428707T1 (de) 2005-12-28 2009-05-15 Union Quimico Farma Verfahren zur herstellung des (s)-enantiomers von omeprazol
EP2000468A1 (en) * 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Esomeprazole salts and processes for preparation thereof
WO2009047775A2 (en) * 2007-10-08 2009-04-16 Hetero Drugs Limited Polymorphs of esomeprazole salts
JP2011513202A (ja) 2008-03-10 2011-04-28 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
BRPI0918492A2 (pt) 2008-09-09 2015-12-01 Astrazeneca Ab uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
EP2445499A4 (en) 2009-06-25 2013-02-27 Astrazeneca Ab METHOD FOR TREATING A PATIENT WITH RISK OF DEVELOPING A NSAID-ASSOCIATED SPURGE
CN102884178B (zh) 2009-12-08 2014-12-03 科德克希思公司 拉唑化合物的合成
HUE037616T2 (hu) 2010-12-08 2018-09-28 Codexis Inc Biokatalizátorok és eljárások armodafinil szintéziséhez
UA115139C2 (uk) 2011-12-28 2017-09-25 Поузен Інк. Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
CN107043367A (zh) * 2017-05-26 2017-08-15 重庆莱美隆宇药业有限公司 一种中性s‑奥美拉唑的干燥工艺
JP2025532389A (ja) 2022-10-04 2025-09-29 ザビリュク，アルセニー 大動脈弁の石灰化の抑制

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027988A1 (en) * 1993-05-28 1994-12-08 Astra Aktiebolag Optically pure salts of pyridinylmethyl sulfinyl-ih-benzimidazole compounds
RU2061693C1 (ru) * 1990-06-07 1996-06-10 Актиеболагет Астра, Способ получения омепразола

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
EE03305B1 (et) * 1994-07-08 2000-12-15 Astra Aktiebolag Paljuosaline tableteeritud annusvorm I

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2061693C1 (ru) * 1990-06-07 1996-06-10 Актиеболагет Астра, Способ получения омепразола
WO1994027988A1 (en) * 1993-05-28 1994-12-08 Astra Aktiebolag Optically pure salts of pyridinylmethyl sulfinyl-ih-benzimidazole compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014035295A1 (ru) 2012-08-30 2014-03-06 Dikovskiy Alexander Vladimirovich Фармацевтическая композиция для лечения гастроэзофагеальной рефлюксной болезни

Also Published As

Publication number Publication date
ZA9711046B (en) 1998-06-22
WO1998028294A1 (en) 1998-07-02
ID21850A (id) 1999-08-05
HUP0001547A3 (en) 2002-06-28
CN1109684C (zh) 2003-05-28
CZ294784B6 (cs) 2005-03-16
EP0946547A1 (en) 1999-10-06
HK1022909A1 (en) 2000-08-25
US6162816A (en) 2000-12-19
HUP0001547A2 (hu) 2002-05-29
SE9604793L (sv) 1998-06-21
EE03923B1 (et) 2002-12-16
NO317191B1 (no) 2004-09-13
TR199901410T2 (xx) 1999-08-23
ATE236898T1 (de) 2003-04-15
AR010361A1 (es) 2000-06-07
PL334297A1 (en) 2000-02-14
SI0946547T1 (en) 2003-10-31
DK0946547T3 (da) 2003-06-30
YU28199A (sh) 2002-03-18
NO993068L (no) 1999-06-21
CA2274076A1 (en) 1998-07-02
HU227589B1 (en) 2011-09-28
CA2274076C (en) 2008-09-30
DE69720774T2 (de) 2004-02-05
EE9900259A (et) 2000-02-15
EP0946547B1 (en) 2003-04-09
TW538039B (en) 2003-06-21
SE9604793D0 (sv) 1996-12-20
NZ336024A (en) 2001-02-23
BR9714059A (pt) 2000-05-09
HU0001547D0 (https=) 2002-05-29
NO993068D0 (no) 1999-06-21
SE510666C2 (sv) 1999-06-14
IS1981B (is) 2005-01-14
IS5070A (is) 1999-06-07
PL190377B1 (pl) 2005-12-30
SK285151B6 (sk) 2006-07-07
SK76599A3 (en) 1999-12-10
ES2194231T3 (es) 2003-11-16
DE69720774D1 (de) 2003-05-15
UA55436C2 (uk) 2003-04-15
MY117032A (en) 2004-04-30
KR20000069595A (ko) 2000-11-25
CZ220299A3 (cs) 2000-02-16
JP4402174B2 (ja) 2010-01-20
AU5502698A (en) 1998-07-17
EG24414A (en) 2009-05-25
JP2001507025A (ja) 2001-05-29
AU730129B2 (en) 2001-02-22
CN1241183A (zh) 2000-01-12
SA97180739B1 (ar) 2006-05-20
IL130450A0 (en) 2000-06-01
RS49685B (sr) 2007-11-15
PT946547E (pt) 2003-07-31

Similar Documents

Publication Publication Date Title
RU2184734C2 (ru) S-омепразол в нейтральной форме, способы его получения, фармацевтическая композиция, содержащая s-омепразол в нейтральной форме, и способ лечения связанного с желудочной кислотой состояния
RU2186778C2 (ru) Натриевая соль омепразола формы б, способ ее получения (варианты) и фармацевтический препарат, содержащий натриевую соль омепразола формы б
JP2012246316A (ja) エソメプラゾールのナトリウム塩の製造に使用するための結晶の改変型の作成方法
MXPA99005661A (en) A novel compound form
HK1022909B (en) A novel compound form
KR20070023757A (ko) 에소메프라졸 나트륨염의 제조에서 사용하기 위한 결정변형의 제조를 위한 신규한 방법
HRP980251A2 (en) New form of a compound
KR20080076924A (ko) 에소메프라졸 비-염 형태의 제조를 위한 신규 방법
HK1184464A (en) New process for preparation of crystal modifications for use in preparation of esomeprazole sodium salt

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20121217